Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials Post published:May 28, 2025 Post category:Analysis/News
Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study Post published:May 27, 2025 Post category:Analysis/News/Pα+
Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar Post published:May 24, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley Post published:May 23, 2025 Post category:Psychedelic Bulletin/Pα+
Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the Road Ahead Post published:May 21, 2025 Post category:Interviews
FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies Post published:May 19, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms, Shots, and the Next Surgeon General; Religious Leaders Study Set to Publish Post published:May 16, 2025 Post category:Psychedelic Bulletin/Pα+
The Interdisciplinary Annotated Psychedelic Research Bibliography of 2024 Post published:May 14, 2025 Post category:2023 Year in Review/Analysis
Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down Post published:May 13, 2025 Post category:Analysis/News/Pα+
Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2) Post published:May 12, 2025 Post category:Analysis/News